LU91326I2 - Vaccin papillomavirus humain Ä6,11,16,18Ü(recombinant, adsorbé) - Google Patents

Vaccin papillomavirus humain Ä6,11,16,18Ü(recombinant, adsorbé)

Info

Publication number
LU91326I2
LU91326I2 LU91326C LU91326C LU91326I2 LU 91326 I2 LU91326 I2 LU 91326I2 LU 91326 C LU91326 C LU 91326C LU 91326 C LU91326 C LU 91326C LU 91326 I2 LU91326 I2 LU 91326I2
Authority
LU
Luxembourg
Prior art keywords
recombinant
adsorbed
human papillomavirus
papillomavirus vaccine
vaccine
Prior art date
Application number
LU91326C
Other languages
English (en)
Other versions
LU91326I9 (fr
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26824774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91326(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of LU91326I2 publication Critical patent/LU91326I2/fr
Publication of LU91326I9 publication Critical patent/LU91326I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LU91326C 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ä6,11,16,18Ü(recombinant, adsorbé) LU91326I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12652899P 1999-03-26 1999-03-26
US09/524,624 US6245568B1 (en) 1999-03-26 2000-03-13 Human papilloma virus vaccine with disassembled and reassembled virus-like particles
PCT/US2000/007595 WO2000057906A1 (fr) 1999-03-26 2000-03-22 Vaccin contre le papillomavirus aux particules viro-induites desassemblees et reassemblees

Publications (2)

Publication Number Publication Date
LU91326I2 true LU91326I2 (fr) 2007-05-14
LU91326I9 LU91326I9 (fr) 2018-12-31

Family

ID=26824774

Family Applications (3)

Application Number Title Priority Date Filing Date
LU91327C LU91327I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ätypes 56,11,16,18Ü(recombinant, adsorbé)
LU91328C LU91328I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)
LU91326C LU91326I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ä6,11,16,18Ü(recombinant, adsorbé)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LU91327C LU91327I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ätypes 56,11,16,18Ü(recombinant, adsorbé)
LU91328C LU91328I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)

Country Status (19)

Country Link
US (2) US6245568B1 (fr)
EP (1) EP1165126B1 (fr)
JP (1) JP4594534B2 (fr)
KR (1) KR20020013516A (fr)
AR (1) AR023166A1 (fr)
AT (1) ATE339222T1 (fr)
AU (1) AU778937B2 (fr)
CA (1) CA2368391C (fr)
CY (4) CY1105779T1 (fr)
DE (4) DE60030698T2 (fr)
DK (1) DK1165126T3 (fr)
ES (1) ES2270822T3 (fr)
FR (1) FR07C0026I2 (fr)
LT (1) LTC1165126I2 (fr)
LU (3) LU91327I2 (fr)
NL (3) NL300269I2 (fr)
PT (1) PT1165126E (fr)
SI (1) SI1165126T1 (fr)
WO (1) WO2000057906A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
WO2001042780A1 (fr) * 1999-12-09 2001-06-14 Medimmune, Inc. Methode de desassemblage-reassemblage in vitro de particules viroides (vlp) du papillomavirus
EP1409013B1 (fr) * 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccins comprenant des adjuvants aluminium et histidine
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2003219760A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10237639A1 (de) * 2002-08-13 2004-02-26 Martin-Luther-Universität Halle-Wittenberg Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ES2649048T3 (es) 2002-11-01 2018-01-09 Glaxosmithkline Biologicals S.A. Procedimiento de secado
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
ATE503492T1 (de) 2002-12-20 2011-04-15 Glaxosmithkline Biolog Sa Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
WO2006004173A1 (fr) * 2004-07-01 2006-01-12 The Circle For The Promotion Of Science And Engineering Construction ressemblant à une particule virale et procédé servant à former celle-ci dans des conditions physiologiques
CN101107022B (zh) * 2005-01-25 2013-07-17 辉瑞爱尔兰药品合伙公司 用于渗滤的方法
WO2007011711A2 (fr) * 2005-07-14 2007-01-25 Mayo Foundation For Medical Education And Research Preparations a base du virus paramyxoviridae
EP1920779A4 (fr) * 2005-08-12 2010-03-10 Astellas Pharma Inc Technique de stabilisation de preparation de yw753
WO2007027076A1 (fr) * 2005-09-01 2007-03-08 Nuno Ayala Jose Luis Formule de stabilisation de vaccins comprenant des antigenes vivants a utiliser dans des systemes de vaccination de masse
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8962262B2 (en) * 2006-05-11 2015-02-24 Arbor Vita Corporation Method of protein extraction from cells
US9207240B2 (en) * 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
US8420128B2 (en) * 2008-03-31 2013-04-16 Morinaga Milk Industry Co., Ltd. Method of imparting heat resistance to lactoferrin
US10190152B2 (en) 2009-09-03 2019-01-29 Becton, Dickinson And Company Methods and compositions for direct chemical lysis
PT3246044T (pt) 2010-08-23 2021-02-15 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
CN104203270A (zh) 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP4098276A1 (fr) 2013-09-08 2022-12-07 Pfizer Inc. Compositions utilisables contre neisseria meningitidis et procédés associés
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
WO2018152505A1 (fr) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Production acellulaire efficace de vecteurs de transfert du gène du virus à papillomes
CN110987571A (zh) * 2019-12-31 2020-04-10 广州金域医学检验中心有限公司 一种单克隆多聚体m蛋白解聚方法
CN111812313B (zh) * 2020-06-22 2021-10-08 北京生物制品研究所有限责任公司 铝佐剂吸附型新型冠状病毒灭活疫苗中抗原的解离方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0971696B1 (fr) * 1997-02-06 2010-06-09 Merck Sharp & Dohme Corp. Conservateurs sans thimerosal pour vaccins
EP0973546B1 (fr) 1997-04-08 2004-03-17 Merck & Co., Inc. Formulations stabilisees du virus du papillome humain
EP1000157A1 (fr) 1997-07-03 2000-05-17 University Technology Corporation Compositions renfermant des capsomeres de papillomavirus humain homogene, leurs procedes de production et leurs procedes d'utilisation en tant qu'agents diagnostiques, prophylactiques ou therapeutiques

Also Published As

Publication number Publication date
SI1165126T1 (sl) 2006-12-31
JP2002540167A (ja) 2002-11-26
KR20020013516A (ko) 2002-02-20
CA2368391C (fr) 2011-06-07
CY2007009I1 (el) 2010-07-28
CY2007010I2 (el) 2009-11-04
CY2007008I1 (el) 2009-11-04
CY2007009I2 (el) 2010-07-28
AR023166A1 (es) 2002-09-04
ATE339222T1 (de) 2006-10-15
CY1105779T1 (el) 2010-07-28
LTC1165126I2 (lt) 2020-04-27
US20010021385A1 (en) 2001-09-13
NL300270I1 (nl) 2007-05-01
LU91327I2 (fr) 2007-05-14
AU778937B2 (en) 2004-12-23
JP4594534B2 (ja) 2010-12-08
LU91328I9 (fr) 2019-03-01
DE122007000033I1 (de) 2007-08-09
ES2270822T3 (es) 2007-04-16
DE60030698T2 (de) 2007-07-19
US6245568B1 (en) 2001-06-12
DE122007000034I1 (de) 2007-08-09
CY2007008I2 (el) 2009-11-04
DK1165126T3 (da) 2007-01-08
LU91326I9 (fr) 2018-12-31
NL300269I1 (nl) 2007-05-01
EP1165126B1 (fr) 2006-09-13
LU91328I2 (fr) 2007-05-14
WO2000057906A1 (fr) 2000-10-05
DE60030698D1 (de) 2006-10-26
LTPA2007002I1 (lt) 2020-03-25
AU3909300A (en) 2000-10-16
LU91327I9 (fr) 2019-03-01
PT1165126E (pt) 2006-12-29
FR07C0026I1 (fr) 2007-04-27
NL300269I2 (nl) 2008-07-01
NL300268I1 (nl) 2007-05-01
FR07C0026I2 (fr) 2012-08-03
CA2368391A1 (fr) 2000-10-05
CY2007010I1 (el) 2009-11-04
DE122007000032I1 (de) 2007-08-09
EP1165126A1 (fr) 2002-01-02

Similar Documents

Publication Publication Date Title
LU91328I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)
ATE413188T1 (de) Menschliche papillomavirus impfstoff- formulierungen
IL158107A0 (en) Human papillomaviruses vaccine
DZ2462A1 (fr) Vaccin antigrippal.
NO20014323L (no) Vaksine
DK1023904T3 (da) Adjuvanser til anvendelse i vacciner
ATE490327T1 (de) Impfstoffzusammensetzung
DZ3219A1 (fr) Vaccin
IL150961A0 (en) Human immunodeficiency virus vaccine
DZ2283A1 (fr) Composition de vaccin.
IL189736A0 (en) Vaccine adjuvants
EP1389043A4 (fr) Vaccin contre le virus de la maladie de la fievre aphteuse
GB9915204D0 (en) Vaccine
HUP0202770A3 (en) Human papilloma virus vaccine
IS2797B (is) Bóluefni gegn ISA-veiru
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
GB9906437D0 (en) Vaccine
GB9913327D0 (en) Vaccine
GB9911823D0 (en) New vaccine formulations
NO20002213D0 (no) Babesia vaksine
GB9909072D0 (en) Vaccine
FR2730936B1 (fr) Vaccin presentant une immunogenicite accrue
ITMI992410A0 (it) Vaccino per hiv
GB9917981D0 (en) Viral vaccine
GB9911825D0 (en) New vaccine formulations